CU20180154A7 - Formulación farmacéutica líquida estable - Google Patents

Formulación farmacéutica líquida estable

Info

Publication number
CU20180154A7
CU20180154A7 CU2018000154A CU20180154A CU20180154A7 CU 20180154 A7 CU20180154 A7 CU 20180154A7 CU 2018000154 A CU2018000154 A CU 2018000154A CU 20180154 A CU20180154 A CU 20180154A CU 20180154 A7 CU20180154 A7 CU 20180154A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
stable liquid
antibody
present
Prior art date
Application number
CU2018000154A
Other languages
English (en)
Other versions
CU24561B1 (es
Inventor
Won Yong Han
Su Hyeon Hong
So Young Kim
Su Jung Kim
Joon Won Lee
Jun Seok Oh
Yeon Kyeong Shin
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20180154(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of CU20180154A7 publication Critical patent/CU20180154A7/es
Publication of CU24561B1 publication Critical patent/CU24561B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

<p>La presente invención proporciona una formulación farmacéutica líquida estable que contiene: un anticuerpo o su fragmento de unión a antígeno; un tensioactivo; un azúcar o su derivado; y un tampón. La formulación farmacéutica líquida estable de acuerdo con Ia presente invención tiene baja viscosidad a Ia vez que contiene un contenido elevado del anticuerpo, tiene una estabilidad durante el almacenamiento a largo plazo excelente basándose en Ia estabilidad excelente en condiciones aceleradas y condiciones severas, y se puede administrar por vía subcutánea.</p>
CU2018000154A 2016-06-30 2017-06-28 Formulación farmacéutica líquida estable CU24561B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30
PCT/KR2017/006855 WO2018004260A1 (ko) 2016-06-30 2017-06-28 안정한 액체 약제학적 제제

Publications (2)

Publication Number Publication Date
CU20180154A7 true CU20180154A7 (es) 2019-08-06
CU24561B1 CU24561B1 (es) 2022-01-13

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000154A CU24561B1 (es) 2016-06-30 2017-06-28 Formulación farmacéutica líquida estable

Country Status (40)

Country Link
US (3) US11951207B2 (es)
EP (2) EP4338752A3 (es)
JP (2) JP7082070B2 (es)
KR (3) KR20180003452A (es)
CN (1) CN109310628A (es)
AU (2) AU2017287743C1 (es)
BR (1) BR112018076377A2 (es)
CA (1) CA3028238C (es)
CL (1) CL2018003662A1 (es)
CO (1) CO2018013689A2 (es)
CR (1) CR20180599A (es)
CU (1) CU24561B1 (es)
DK (1) DK3479819T5 (es)
DO (1) DOP2018000290A (es)
EA (1) EA201892653A1 (es)
EC (1) ECSP18093651A (es)
ES (1) ES2975782T3 (es)
FI (1) FI3479819T3 (es)
GE (1) GEP20217249B (es)
HR (1) HRP20240426T1 (es)
HU (1) HUE066142T2 (es)
IL (1) IL263630B2 (es)
JO (1) JOP20180125B1 (es)
LT (1) LT3479819T (es)
MA (1) MA45562B1 (es)
MD (1) MD3479819T2 (es)
MX (1) MX2018015960A (es)
NI (1) NI201800139A (es)
PE (1) PE20190448A1 (es)
PH (1) PH12018502670A1 (es)
PL (1) PL3479819T3 (es)
PT (1) PT3479819T (es)
RS (1) RS65395B1 (es)
SG (1) SG11201811320YA (es)
SI (1) SI3479819T1 (es)
TN (1) TN2018000443A1 (es)
TW (1) TWI736643B (es)
UA (1) UA122610C2 (es)
WO (1) WO2018004260A1 (es)
ZA (1) ZA201808476B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN110167531A (zh) * 2017-01-11 2019-08-23 赛特瑞恩股份有限公司 稳定的液体调配物
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
JP7374544B2 (ja) * 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
EP3941521A1 (en) * 2019-03-18 2022-01-26 Alvotech HF Aqueous formulations of tnf-alpha antibodies in high concentrations
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
KR20220152540A (ko) * 2020-03-13 2022-11-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
KR20240073051A (ko) * 2021-09-16 2024-05-24 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
TW202333788A (zh) * 2021-12-28 2023-09-01 大陸商江蘇先聲藥業有限公司 一種抗ｔｎｆｒ２抗體藥物組合物
WO2024124177A2 (en) * 2022-12-09 2024-06-13 Xentria, Inc. Methods of treating sarcoidosis with a tnf-α antibody and associated compositions and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994011041A1 (en) 1992-11-19 1994-05-26 R G S.A.S. Di Rosaria Galli & C. Disposable auto-injector for prefilled syringes
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
KR101671886B1 (ko) 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
KR20120038406A (ko) 2009-05-04 2012-04-23 애보트 바이오테크놀로지 리미티드 인간 항?ＴＮＦ?α 항체의 안정한 고 단백질 농도 제형
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
MX357393B (es) * 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
HUE049282T2 (hu) 2012-09-07 2020-09-28 Coherus Biosciences Inc Adalimumab stabil vizes formulációi
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
EP2906599B1 (en) * 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
CA2885862A1 (en) * 2012-10-25 2014-05-01 Medimmune, Llc Stable, low viscosity antibody formulation
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
CA2898262A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN104666242B (zh) 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
CA2944330A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
DK2946765T3 (en) * 2014-05-23 2016-10-31 Ares Trading Sa Liquid pharmaceutical composition
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
RU2017131618A (ru) * 2015-02-13 2019-03-13 Санофи Стабильный жидкий состав для моноклональных антител
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
EP3479819B1 (en) 2024-01-24
KR20180003452A (ko) 2018-01-09
US20240269069A1 (en) 2024-08-15
CA3028238C (en) 2024-01-02
RS65395B1 (sr) 2024-04-30
EA201892653A1 (ru) 2019-05-31
PE20190448A1 (es) 2019-03-29
HUE066142T2 (hu) 2024-07-28
US11951207B2 (en) 2024-04-09
KR20180097471A (ko) 2018-08-31
CA3028238A1 (en) 2018-01-04
JOP20180125B1 (ar) 2022-09-15
CN109310628A (zh) 2019-02-05
AU2020201249A1 (en) 2020-03-12
TWI736643B (zh) 2021-08-21
CL2018003662A1 (es) 2019-03-15
MA45562B1 (fr) 2024-05-31
UA122610C2 (uk) 2020-12-10
LT3479819T (lt) 2024-04-25
PT3479819T (pt) 2024-04-15
CO2018013689A2 (es) 2019-01-18
KR20210042052A (ko) 2021-04-16
DK3479819T3 (da) 2024-04-15
JP2019525902A (ja) 2019-09-12
EP4338752A2 (en) 2024-03-20
SG11201811320YA (en) 2019-01-30
MA45562A (fr) 2019-05-08
NI201800139A (es) 2019-03-25
NZ748101A (en) 2020-11-27
ZA201808476B (en) 2020-08-26
US20210000743A1 (en) 2021-01-07
AU2017287743C1 (en) 2020-10-01
JP2022122941A (ja) 2022-08-23
SI3479819T1 (sl) 2024-06-28
TN2018000443A1 (en) 2020-06-15
BR112018076377A2 (pt) 2019-03-26
EP3479819A4 (en) 2020-02-26
IL263630B2 (en) 2023-06-01
US20240269071A1 (en) 2024-08-15
WO2018004260A1 (ko) 2018-01-04
GEP20217249B (en) 2021-04-26
AU2020201249B2 (en) 2021-07-15
JOP20180125A1 (ar) 2019-01-30
ES2975782T3 (es) 2024-07-15
AU2017287743A1 (en) 2018-11-22
JP7405324B2 (ja) 2023-12-26
MX2018015960A (es) 2019-03-21
EP4338752A3 (en) 2024-04-03
PH12018502670A1 (en) 2019-10-07
HRP20240426T1 (hr) 2024-06-21
KR102229274B1 (ko) 2021-03-18
KR102397713B1 (ko) 2022-05-13
EP3479819A1 (en) 2019-05-08
IL263630A (en) 2019-01-31
PL3479819T3 (pl) 2024-07-01
JP7082070B2 (ja) 2022-06-07
DOP2018000290A (es) 2019-02-15
DK3479819T5 (da) 2024-09-09
CU24561B1 (es) 2022-01-13
FI3479819T3 (fi) 2024-04-17
MD3479819T2 (ro) 2024-07-31
TW201806617A (zh) 2018-03-01
AU2017287743B2 (en) 2020-01-30
CR20180599A (es) 2019-04-09
ECSP18093651A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
CU20180154A7 (es) Formulación farmacéutica líquida estable
MX2021005907A (es) Formulaciones de proteinas liquidas que contienen liquidos ionicos.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
AR098168A1 (es) Formulación estable de insulina glulisina
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
CO7111300A2 (es) Formulación de anticuerpos
GT201400285A (es) Formulacion de anticuerpos
MX2017004306A (es) Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
PE20150190A1 (es) Formulacion farmaceutica
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
BR112015026810A2 (pt) método para fornecer um sistema óptico montado à cabeça
EA201691132A1 (ru) Инъекционное средство и способ образования депо
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds
MY194758A (en) Stable liquid pharmaceutical formulation
BR112017010459A2 (pt) dispositivo para transporte da luz
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
TH1701002015A (th) องค์ประกอบวัคซีนที่การเกิดฟองลดลง
UA113120C2 (xx) Гарбузове варення &#34;екстоп&#34;